Related Experiment Video
Updated: Jul 18, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Trilostane in advanced breast cancer
John R Puddefoot1, Stewart Barker, Gavin P Vinson
1School of Biological and Chemical Sciences, Queen Mary, University of London, Mile End Road, London, E1 4NS, UK. J.R.Puddefoot@qmul.ac.uk
Expert Opinion on Pharmacotherapy
|November 18, 2006
Summary
Trilostane offers a novel endocrine therapy for advanced breast cancer, particularly for patients resistant to tamoxifen and aromatase inhibitors. This allosteric modulator of the estrogen receptor shows promise in clinical trials for relapsed cases.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Established therapies for advanced postmenopausal breast cancer include antiestrogens (e.g., tamoxifen) and aromatase inhibitors.
- Acquired resistance to these endocrine treatments limits therapeutic options, often resorting to switching to alternative agents.
- Trilostane presents a novel therapeutic strategy due to its distinct mechanism of action.
Purpose of the Study:
- To evaluate trilostane as an alternative endocrine treatment for advanced breast cancer.
- To investigate trilostane's efficacy in patients resistant to prior endocrine therapies.
- To explore trilostane's potential in premenopausal breast cancer and other malignancies like prostate cancer.
Main Methods:
- Trilostane functions as an allosteric modulator of the estrogen receptor.
- It targets both estrogen- and growth factor-dependent pathways involved in estradiol-stimulated cell proliferation.
- Clinical trials were conducted to assess its effectiveness in relevant patient populations.
Main Results:
- Trilostane demonstrated efficacy in clinical trials for breast cancer patients with disease relapse after prior endocrine therapy.
- The drug's unique mode of action provides an alternative for endocrine-resistant cases.
- Ongoing trials are exploring its use in premenopausal breast cancer and prostate cancer.
Conclusions:
- Trilostane is an effective alternative endocrine treatment for advanced breast cancer, especially in cases of resistance.
- Its mechanism of action offers a new approach to targeting cancer cell proliferation.
- Further research is warranted to expand its application to other cancer types and patient groups.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...